Biogen Inc. (NASDAQ:BIIB) Stifel 2025 Virtual CNS Forum Conference March 18, 2025 10:15 AM ET
Company Participants
Priya Singhal – Head of Development
Conference Call Participants
Paul Matteis – Stifel
Paul Matteis
Great. Good morning, everybody. Happy to be moderating my annual panel where Priya has to listen to me pepper her with questions for 40 minutes or so with Priya Singhal, Head of Development at Biogen.
Thank you, Priya for joining as always. I’m going to kick it over to you to just make some opening remarks on Biogen and give us a snapshot of the development portfolio, and then we can do Q&A. So thanks again and take it away.
Priya Singhal
Thank you, Paul. Thanks for having me. It’s always a pleasure to join you. So before we begin, I’d like to point out that we will be making — that I will be making forward-looking statements, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult the risk factors discussed in our SEC filings for additional detail.
So really excited to be here, Paul. As you may know, that over the last two years, we’ve really focused on efforts to augment the pipeline. And the main goal has been rebalancing the risk profile and investing to win in key areas of expected future growth. So in 2024, I think we made a lot of progress in our pipeline, where we’ve prioritized key programs, internal programs, where we believe that we have the opportunity and potential to win such as Alzheimer’s, where we were able to amend our Phase II study, CELIA for BIIB080 and accelerate a potential proof-of-concept readout next year in 2026.
We also got
Read the full article here
